Triple A Syndrome

Genetic MONDO:0009279 Pathograph 22 Show in embeddings browser Nucleoporin-related disorder Adrenal insufficiency Neurodegenerative disease

Triple A syndrome (Allgrove syndrome) is a rare autosomal recessive multisystem disorder caused by biallelic loss-of-function variants in AAAS, which encodes the nuclear pore complex protein ALADIN. It is classically defined by a triad of achalasia of the oesophageal cardia, alacrima (deficient tear secretion), and adrenocorticotropin (ACTH)-resistant primary adrenal insufficiency, with variable and often progressive neurological involvement (peripheral and central neuropathy, autonomic dysfunction, cerebellar ataxia, and mild dementia). Disease-associated ALADIN mutants fail to target the nuclear pore complex and selectively impair nucleocytoplasmic import of DNA-repair factors, rendering cells hypersensitive to oxidative stress; this cell-type-specific defect in nuclear transport underlies the degeneration of adrenocortical, neuronal, lacrimal, and oesophageal tissues. Clinical manifestations are heterogeneous and can present unusually late in life.

Ask OpenScientist

Ask a research question about Triple A Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
12
Phenotypes
22
Pathograph
1
Genes
5
Medical Actions
1
Deep Research
🏷

Classifications

Harrison's Part
GENETICS ENVIRONMENT DISEASE ENDOCRINOLOGY METABOLISM
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Triple A syndrome is inherited in an autosomal recessive manner; affected individuals carry biallelic (homozygous or compound heterozygous) pathogenic variants in AAAS.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"Triple A syndrome, also known as Allgrove syndrome, is a rare autosomal recessive disorder, characterised by achalasia, alacrima, and adrenal insufficiency."
Establishes the autosomal recessive inheritance pattern and the defining clinical triad.
⚙

Pathophysiology

5
ALADIN loss and nuclear pore complex mislocalization
ALADIN is a WD-repeat nucleoporin that normally localizes to the nuclear pore complex (NPC), the sole gateway for nucleocytoplasmic transport. Disease-associated missense, nonsense, and frameshift AAAS mutations fail to target ALADIN to the NPC, leaving it mislocalized in the cytoplasm. Nuclear envelopes and NPCs are structurally normal, so disease arises from a defect in NPC function rather than structure.
AAAS hgnc:13666 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves AAAS (hgnc:13666). hgnc:13666 is a gene from the HUGO Gene Nomenclature Committee.
nucleocytoplasmic transport GO:0006913 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves nucleocytoplasmic transport (GO:0006913). GO:0006913 is a biological process from the Gene Ontology.
nuclear pore GO:0005643 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves nuclear pore (GO:0005643). GO:0005643 is a cellular component from the Gene Ontology.
Downstream
Selective failure of nuclear protein import NPC mistargeting of ALADIN disrupts NPC function and selective nuclear import.
Show evidence (2 references)
PMID:12730363 SUPPORT In Vitro
"We showed previously that ALADIN localizes to nuclear pore complexes (NPCs), large multiprotein assemblies that are the sole sites of nucleocytoplasmic transport."
Establishes ALADIN as a nuclear pore complex protein central to nucleocytoplasmic transport.
PMID:12730363 SUPPORT In Vitro
"A variety of disease-associated missense, nonsense, and frameshift mutations failed to localize to NPCs and were found predominantly in the cytoplasm."
Shows disease mutations mislocalize ALADIN away from the NPC into the cytoplasm.
Selective failure of nuclear protein import
Mistargeted ALADIN selectively impairs the karyopherin (importin) alpha/beta-mediated import pathway, decreasing nuclear accumulation of specific cargoes including the DNA single-strand-break repair protein aprataxin (APTX) and DNA ligase I, while sparing other import pathways.
protein import into nucleus GO:0006606 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves protein import into nucleus (GO:0006606). GO:0006606 is a biological process from the Gene Ontology.
nuclear pore GO:0005643 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves nuclear pore (GO:0005643). GO:0005643 is a cellular component from the Gene Ontology.
Downstream
Impaired DNA repair and oxidative stress hypersensitivity Reduced nuclear import of aprataxin and DNA ligase I compromises repair of DNA single-strand breaks.
Show evidence (1 reference)
PMID:16467144 SUPPORT In Vitro
"ALADIN(I482S) affected a karyopherin-alpha/beta-mediated import pathway and decreased nuclear accumulations of aprataxin (APTX), a repair protein for DNA single-strand breaks (SSBs), and of DNA ligase I in I482Sf."
Demonstrates selective impairment of nuclear import of DNA-repair proteins by mutant ALADIN.
Impaired DNA repair and oxidative stress hypersensitivity
Deficient nuclear delivery of DNA single-strand-break repair machinery renders triple A syndrome cells hypersensitive to oxidative stress: on glutathione depletion, patient fibroblasts accumulate DNA single-strand breaks that they can no longer sufficiently repair. This nuclear oxidative vulnerability is proposed as a primary driver of the tissue-specific degeneration.
single strand break repair GO:0000012 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves single strand break repair (GO:0000012). GO:0000012 is a biological process from the Gene Ontology. DNA repair GO:0006281 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves DNA repair (GO:0006281). GO:0006281 is a biological process from the Gene Ontology. response to oxidative stress GO:0006979 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves response to oxidative stress (GO:0006979). GO:0006979 is a biological process from the Gene Ontology.
Downstream
Tissue-specific cellular degeneration Accumulated oxidative DNA damage in vulnerable cell types drives their degeneration.
Show evidence (2 references)
PMID:16467144 SUPPORT In Vitro
"Cell survival assay showed hypersensitivity of I482Sf to l-buthionine-(S,R)-sulfoximine (BSO), a glutathione-depleting agent."
Demonstrates hypersensitivity of patient cells to oxidative (glutathione-depleting) stress.
PMID:16467144 SUPPORT In Vitro
"These observations implied that I482Sf are hypersensitive to BSO and no longer sufficiently repair SSBs."
Links oxidative stress to an unrepaired DNA single-strand-break burden in patient cells.
Tissue-specific cellular degeneration
The ALADIN nucleocytoplasmic-transport defect selectively affects tissues with high expression and dependence, producing adrenocortical failure, peripheral and central neurodegeneration, autonomic dysfunction, lacrimal gland hypofunction (alacrima), and oesophageal motor dysfunction (achalasia). ALADIN is expressed in neuroendocrine and cerebral structures, consistent with a role in normal development and maintenance of the peripheral and central nervous systems.
cortical cell of adrenal gland CL:0002097 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cortical cell of adrenal gland (CL:0002097). CL:0002097 is a cell type from the Cell Ontology. neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology. autonomic neuron CL:0000107 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves autonomic neuron (CL:0000107). CL:0000107 is a cell type from the Cell Ontology.
adrenal gland UBERON:0002369 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in adrenal gland (UBERON:0002369). UBERON:0002369 is an anatomical location from the Uberon multi-species anatomy ontology. lacrimal gland UBERON:0001817 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in lacrimal gland (UBERON:0001817). UBERON:0001817 is an anatomical location from the Uberon multi-species anatomy ontology. esophagus UBERON:0001043 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in esophagus (UBERON:0001043). UBERON:0001043 is an anatomical location from the Uberon multi-species anatomy ontology. peripheral nervous system UBERON:0000010 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in peripheral nervous system (UBERON:0000010). UBERON:0000010 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
ACTH-resistant adrenal cortical failure Degeneration of adrenocortical cells produces ACTH-resistant glucocorticoid deficiency.
Achalasia Oesophageal tissue and autonomic dysfunction produce achalasia.
Dysphagia Achalasia caused by oesophageal dysfunction produces dysphagia.
Alacrima Lacrimal gland and autonomic dysfunction produce alacrima.
Peripheral neuropathy Peripheral neuronal degeneration produces peripheral neuropathy.
Autonomic dysfunction Degeneration and abnormal development of autonomic neurons produce dysautonomia.
Cerebellar ataxia Central neurodegeneration produces progressive cerebellar ataxia.
Dementia Central neurodegeneration produces cognitive decline and dementia.
Optic atrophy Progressive neurological degeneration can produce optic atrophy.
Skeletal muscle atrophy Progressive neurological degeneration can produce amyotrophy.
Show evidence (1 reference)
PMID:11062474 SUPPORT Human Clinical
"The expression of the gene in both neuroendocrine and cerebral structures points to a role in the normal development of the peripheral and central nervous systems."
Supports tissue-specific (neuroendocrine and CNS) vulnerability driven by ALADIN expression pattern.
ACTH-resistant adrenal cortical failure
Selective loss of adrenocortical function produces isolated glucocorticoid deficiency that does not respond to ACTH, the endocrine hallmark of the syndrome and a potentially life-threatening feature if unrecognized.
cortical cell of adrenal gland CL:0002097 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cortical cell of adrenal gland (CL:0002097). CL:0002097 is a cell type from the Cell Ontology.
adrenal cortex UBERON:0001235 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in adrenal cortex (UBERON:0001235). UBERON:0001235 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
ACTH-resistant primary adrenal insufficiency Adrenal cortical failure directly manifests as primary adrenal insufficiency.
Hyperpigmentation of the skin Adrenal insufficiency with elevated ACTH can manifest as mucocutaneous hyperpigmentation.
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"He was diagnosed with primary adrenal insufficiency in childhood and substituted with fludrocortisone and hydrocortisone."
Documents primary adrenal insufficiency managed with corticosteroid replacement.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Triple A Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Digestive 1
Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"We report a case of a 51-year-old male patient with recurring symptoms of dysphagia due to achalasia"
Dysphagia is the clinical manifestation of oesophageal achalasia in triple A syndrome.
Eye 1
Optic atrophy HP:0000648 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Optic atrophy (HP:0000648). HP:0000648 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20687490 SUPPORT Human Clinical
"Polyneuropathy, amyotrophy, optic atrophy are the other common neurological problems."
Lists optic atrophy among the neurological manifestations.
Integument 2
Hyperpigmentation of the skin HP:0000953 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperpigmentation of the skin (HP:0000953). HP:0000953 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:25554662 SUPPORT Human Clinical
"presented oral hyperpigmentation and diffused acquired melanoderma"
Documents oral and diffuse cutaneous hyperpigmentation.
Palmoplantar hyperkeratosis FREQUENT Palmoplantar keratoderma HP:0000982 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Palmoplantar keratoderma (HP:0000982). HP:0000982 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36194344 SUPPORT Human Clinical
"In addition, hyperreflexia(6/12), learning disability(5/12), hypernasal speech(5/12), muscle weakness(8/12), delayed walking(7/12), delayed speech(6/12), excessive sweating(7/12), optic atrophy(1/12), epilepsy(1/12), palmoplantar hyperkeratosis(5/12), multiple dental caries(9/12), atrophy of the..."
Documents palmoplantar hyperkeratosis in 5 of 12 patients, supporting the FREQUENT band (30-79%).
Musculoskeletal 1
Skeletal muscle atrophy HP:0003202 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Skeletal muscle atrophy (HP:0003202). HP:0003202 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20687490 SUPPORT Human Clinical
"Polyneuropathy, amyotrophy, optic atrophy are the other common neurological problems."
Lists amyotrophy among the neurological manifestations.
Nervous System 4
Peripheral neuropathy HP:0009830 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Peripheral neuropathy (HP:0009830). HP:0009830 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"The Schirmer test confirmed total alacrima, and neurological testing showed mild peripheral and central neuropathy."
Documents peripheral (and central) neuropathy in an affected patient.
Autonomic dysfunction Abnormal autonomic nervous system physiology HP:0012332 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autonomic dysfunction, annotated with Abnormal autonomic nervous system physiology (HP:0012332). HP:0012332 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:11062474 SUPPORT Human Clinical
"several lines of evidence indicate that triple-A syndrome results from the abnormal development of the autonomic nervous system"
Supports autonomic nervous system involvement as an intrinsic feature.
PMID:36194344 SUPPORT Human Clinical
"In addition, hyperreflexia(6/12), learning disability(5/12), hypernasal speech(5/12), muscle weakness(8/12), delayed walking(7/12), delayed speech(6/12), excessive sweating(7/12), optic atrophy(1/12), epilepsy(1/12), palmoplantar hyperkeratosis(5/12), multiple dental caries(9/12), atrophy of the..."
Documents sudomotor autonomic dysfunction in 7 of 12 patients.
Cerebellar ataxia Progressive cerebellar ataxia HP:0002073 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive cerebellar ataxia (HP:0002073). HP:0002073 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:11062474 SUPPORT Human Clinical
"late-onset progressive neurological symptoms (including cerebellar ataxia, peripheral neuropathy and mild dementia) suggest that the central nervous system may be involved in the disease as well"
Cerebellar ataxia is part of the late-onset progressive CNS phenotype.
Dementia HP:0000726 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mild dementia, annotated with Dementia (HP:0000726). HP:0000726 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:11062474 SUPPORT Human Clinical
"late-onset progressive neurological symptoms (including cerebellar ataxia, peripheral neuropathy and mild dementia) suggest that the central nervous system may be involved in the disease as well"
Mild dementia is part of the late-onset progressive CNS phenotype.
Other 3
Achalasia HP:0002571 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Achalasia (HP:0002571). HP:0002571 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:11062474 SUPPORT Human Clinical
"an autosomal recessive disorder characterized by adrenocorticotropin hormone (ACTH)-resistant adrenal insufficiency, achalasia of the oesophageal cardia and alacrima"
Achalasia of the oesophageal cardia is one of the three defining features.
Alacrima HP:0000522 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Alacrima (HP:0000522). HP:0000522 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"The Schirmer test confirmed total alacrima, and neurological testing showed mild peripheral and central neuropathy."
Documents alacrima (confirmed by Schirmer test) as a cardinal feature.
ACTH-resistant primary adrenal insufficiency HP:0008207 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is ACTH-resistant primary adrenal insufficiency, annotated with Primary adrenal insufficiency (HP:0008207). HP:0008207 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:11062474 SUPPORT Human Clinical
"an autosomal recessive disorder characterized by adrenocorticotropin hormone (ACTH)-resistant adrenal insufficiency, achalasia of the oesophageal cardia and alacrima"
Establishes ACTH-resistant adrenal insufficiency as a defining feature.
🧬

Genetic Associations

1
AAAS pathogenic variants (Loss-of-function)
Gene: AAAS hgnc:13666 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is AAAS (hgnc:13666). hgnc:13666 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:11062474 SUPPORT Human Clinical
"identified a novel gene (AAAS) encoding a protein of 547 amino acids that is mutant in affected individuals"
Identifies AAAS as the causative gene of triple-A syndrome.
PMID:42415167 SUPPORT Human Clinical
"Long-read sequencing confirmed compound heterozygosity for two point mutations in the AAAS gene: a missense mutation, ENST00000209873.9:c.938T>A (p.Val313Asp) in exon 10, and a novel nonsense mutation, ENST00000209873.9:c.1264C>T (p.Gln422Ter) in exon 14."
Documents biallelic (compound heterozygous) AAAS variants confirmed in trans.
💊

Medical Actions

5
Glucocorticoid replacement (hydrocortisone)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: hydrocortisone CHEBI:17650 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses hydrocortisone, annotated with cortisol (CHEBI:17650). CHEBI:17650 is a therapeutic agent from Chemical Entities of Biological Interest.
Lifelong glucocorticoid replacement with hydrocortisone corrects the ACTH-resistant glucocorticoid deficiency and prevents adrenal crisis.
Mechanism Target:
BYPASSES ACTH-resistant adrenal cortical failure — Exogenous glucocorticoid bypasses failed endogenous cortisol production.
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"He was diagnosed with primary adrenal insufficiency in childhood and substituted with fludrocortisone and hydrocortisone."
Hydrocortisone replacement is used to manage the adrenal insufficiency of triple A syndrome.
Target Phenotypes: ACTH-resistant primary adrenal insufficiency HP:0008207 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets ACTH-resistant primary adrenal insufficiency, annotated with Primary adrenal insufficiency (HP:0008207). HP:0008207 is a phenotype from the Human Phenotype Ontology.
Mineralocorticoid replacement (fludrocortisone)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: fludrocortisone CHEBI:50885 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses fludrocortisone (CHEBI:50885). CHEBI:50885 is a therapeutic agent from Chemical Entities of Biological Interest.
Fludrocortisone provides mineralocorticoid replacement when the adrenal insufficiency includes a mineralocorticoid component.
Mechanism Target:
BYPASSES ACTH-resistant adrenal cortical failure — Exogenous mineralocorticoid bypasses deficient endogenous adrenal output.
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"He was diagnosed with primary adrenal insufficiency in childhood and substituted with fludrocortisone and hydrocortisone."
Fludrocortisone replacement is part of the corticosteroid substitution used in triple A syndrome.
Target Phenotypes: ACTH-resistant primary adrenal insufficiency HP:0008207 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets ACTH-resistant primary adrenal insufficiency, annotated with Primary adrenal insufficiency (HP:0008207). HP:0008207 is a phenotype from the Human Phenotype Ontology.
Heller myotomy for achalasia
Action: Heller MyotomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Heller Myotomy (NCIT:C157873). NCIT:C157873 is a clinical intervention from the NCI Thesaurus. NCIT:C157873
Surgical Heller myotomy relieves the functional obstruction of oesophageal achalasia and its associated dysphagia.
Target Phenotypes: Achalasia HP:0002571 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Achalasia (HP:0002571). HP:0002571 is a phenotype from the Human Phenotype Ontology. Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"recurring symptoms of dysphagia due to achalasia, who was previously treated by Heller myotomy and repeated endoscopic dilations"
Documents Heller myotomy as management for achalasia.
Endoscopic dilation for achalasia
Action: Esophageal DilationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Esophageal Dilation (NCIT:C70908). NCIT:C70908 is a clinical intervention from the NCI Thesaurus. NCIT:C70908
Repeated endoscopic dilation lowers functional oesophageal obstruction and relieves dysphagia.
Target Phenotypes: Achalasia HP:0002571 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Achalasia (HP:0002571). HP:0002571 is a phenotype from the Human Phenotype Ontology. Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"recurring symptoms of dysphagia due to achalasia, who was previously treated by Heller myotomy and repeated endoscopic dilations"
Documents repeated endoscopic dilation as management for achalasia.
Ocular lubrication for alacrima
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Supportive ocular lubrication (artificial tears) protects the ocular surface from the keratopathy risk of deficient tear production.
Target Phenotypes: Alacrima HP:0000522 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Alacrima (HP:0000522). HP:0000522 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20687490 SUPPORT Human Clinical
"Alacrimia is treated with artificial tears"
Directly supports artificial tears for alacrima.
🔬

Diagnosis

2
Schirmer tear-production test
Schirmer testing objectively demonstrates deficient tear production and supports the alacrima component of the diagnostic triad.
laboratory procedure NCIT:C25294 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"The Schirmer test confirmed total alacrima"
Documents objective confirmation of alacrima by Schirmer testing.
AAAS molecular genetic testing
Molecular analysis establishes biallelic pathogenic AAAS variants and can confirm Triple A syndrome when the clinical triad is incomplete.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:42415167 SUPPORT Human Clinical
"Long-read sequencing confirmed compound heterozygosity for two point mutations in the AAAS gene"
Documents molecular confirmation of biallelic AAAS variants.
📊

Prevalence

1
Worldwide
Unknown Rare
Triple A syndrome is a rare disorder reported worldwide. A robust numeric population prevalence estimate is not established, so no rate is inferred.
Show evidence (1 reference)
PMID:20687490 SUPPORT Human Clinical
"It is a rare disease"
Directly supports classifying Triple A syndrome as rare.
{ }

Source YAML

click to show 
name: Triple A Syndrome
creation_date: '2026-07-13T23:30:00Z'
category: Genetic
synonyms:
- Allgrove syndrome
- AAA syndrome
- achalasia-addisonianism-alacrima syndrome
- adrenal insufficiency-achalasia-alacrima syndrome
- ALADIN deficiency
description: >-
  Triple A syndrome (Allgrove syndrome) is a rare autosomal recessive
  multisystem disorder caused by biallelic loss-of-function variants in AAAS,
  which encodes the nuclear pore complex protein ALADIN. It is classically
  defined by a triad of achalasia of the oesophageal cardia, alacrima
  (deficient tear secretion), and adrenocorticotropin (ACTH)-resistant primary
  adrenal insufficiency, with variable and often progressive neurological
  involvement (peripheral and central neuropathy, autonomic dysfunction,
  cerebellar ataxia, and mild dementia). Disease-associated ALADIN mutants fail
  to target the nuclear pore complex and selectively impair nucleocytoplasmic
  import of DNA-repair factors, rendering cells hypersensitive to oxidative
  stress; this cell-type-specific defect in nuclear transport underlies the
  degeneration of adrenocortical, neuronal, lacrimal, and oesophageal tissues.
  Clinical manifestations are heterogeneous and can present unusually late in
  life.
disease_term:
  preferred_term: triple-A syndrome
  term:
    id: MONDO:0009279
    label: triple-A syndrome
parents:
- Nucleoporin-related disorder
- Adrenal insufficiency
- Neurodegenerative disease
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  - classification_value: ENDOCRINOLOGY_METABOLISM
prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: RARE
  notes: >-
    Triple A syndrome is a rare disorder reported worldwide. A robust numeric
    population prevalence estimate is not established, so no rate is inferred.
  evidence:
  - reference: PMID:20687490
    reference_title: Triple-A syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It is a rare disease
    explanation: Directly supports classifying Triple A syndrome as rare.
inheritance:
- name: Autosomal recessive inheritance
  description: >-
    Triple A syndrome is inherited in an autosomal recessive manner; affected
    individuals carry biallelic (homozygous or compound heterozygous)
    pathogenic variants in AAAS.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Triple A syndrome, also known as Allgrove syndrome, is a rare autosomal recessive disorder, characterised by achalasia, alacrima, and adrenal insufficiency."
    explanation: Establishes the autosomal recessive inheritance pattern and the defining clinical triad.
genetic:
- name: AAAS pathogenic variants
  gene_term:
    preferred_term: AAAS
    term:
      id: hgnc:13666
      label: AAAS
  association: Loss-of-function
  presence: Positive
  notes: >-
    AAAS encodes ALADIN, a 547-amino-acid WD-repeat protein of the nuclear pore
    complex. Truncating, missense, and splice-site variants are described;
    compound heterozygous point mutations (e.g., c.938T>A p.Val313Asp and the
    nonsense c.1264C>T p.Gln422Ter) have been confirmed in trans by long-read
    sequencing.
  evidence:
  - reference: PMID:11062474
    reference_title: "Mutant WD-repeat protein in triple-A syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identified a novel gene (AAAS) encoding a protein of 547 amino acids that is mutant in affected individuals"
    explanation: Identifies AAAS as the causative gene of triple-A syndrome.
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Long-read sequencing confirmed compound heterozygosity for two point mutations in the AAAS gene: a missense mutation, ENST00000209873.9:c.938T>A (p.Val313Asp) in exon 10, and a novel nonsense mutation, ENST00000209873.9:c.1264C>T (p.Gln422Ter) in exon 14."
    explanation: Documents biallelic (compound heterozygous) AAAS variants confirmed in trans.
phenotypes:
- category: Gastrointestinal
  name: Achalasia
  description: >-
    Achalasia of the oesophageal cardia with impaired lower oesophageal
    sphincter relaxation, producing dysphagia; may require Heller myotomy and
    repeated endoscopic dilation.
  phenotype_term:
    preferred_term: Achalasia
    term:
      id: HP:0002571
      label: Achalasia
  evidence:
  - reference: PMID:11062474
    reference_title: "Mutant WD-repeat protein in triple-A syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an autosomal recessive disorder characterized by adrenocorticotropin hormone (ACTH)-resistant adrenal insufficiency, achalasia of the oesophageal cardia and alacrima"
    explanation: Achalasia of the oesophageal cardia is one of the three defining features.
- category: Gastrointestinal
  name: Dysphagia
  description: >-
    Difficulty swallowing secondary to oesophageal achalasia, a common
    presenting complaint.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report a case of a 51-year-old male patient with recurring symptoms of dysphagia due to achalasia"
    explanation: Dysphagia is the clinical manifestation of oesophageal achalasia in triple A syndrome.
- category: Ophthalmologic
  name: Alacrima
  description: >-
    Deficient or absent tear production, typically the earliest and most
    consistent feature, confirmed by an abnormal Schirmer test.
  phenotype_term:
    preferred_term: Alacrima
    term:
      id: HP:0000522
      label: Alacrima
  evidence:
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Schirmer test confirmed total alacrima, and neurological testing showed mild peripheral and central neuropathy."
    explanation: Documents alacrima (confirmed by Schirmer test) as a cardinal feature.
- category: Endocrine
  name: ACTH-resistant primary adrenal insufficiency
  description: >-
    Primary adrenal insufficiency with isolated glucocorticoid deficiency that
    is resistant to adrenocorticotropic hormone (ACTH); often presents in
    childhood and requires lifelong corticosteroid replacement.
  phenotype_term:
    preferred_term: ACTH-resistant primary adrenal insufficiency
    term:
      id: HP:0008207
      label: Primary adrenal insufficiency
  evidence:
  - reference: PMID:11062474
    reference_title: "Mutant WD-repeat protein in triple-A syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an autosomal recessive disorder characterized by adrenocorticotropin hormone (ACTH)-resistant adrenal insufficiency, achalasia of the oesophageal cardia and alacrima"
    explanation: Establishes ACTH-resistant adrenal insufficiency as a defining feature.
- category: Neurological
  name: Peripheral neuropathy
  description: >-
    Progressive peripheral neuropathy, often part of a broader late-onset
    neurodegenerative picture.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Schirmer test confirmed total alacrima, and neurological testing showed mild peripheral and central neuropathy."
    explanation: Documents peripheral (and central) neuropathy in an affected patient.
- category: Neurological
  name: Autonomic dysfunction
  description: >-
    Dysfunction of the autonomic nervous system, attributed to abnormal
    development and degeneration of autonomic neurons.
  phenotype_term:
    preferred_term: Autonomic dysfunction
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
  evidence:
  - reference: PMID:11062474
    reference_title: "Mutant WD-repeat protein in triple-A syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "several lines of evidence indicate that triple-A syndrome results from the abnormal development of the autonomic nervous system"
    explanation: Supports autonomic nervous system involvement as an intrinsic feature.
  - reference: PMID:36194344
    reference_title: "The clinical and laboratory features of patients with triple A syndrome: a single-center experience in Turkey."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, hyperreflexia(6/12), learning disability(5/12), hypernasal
      speech(5/12), muscle weakness(8/12), delayed walking(7/12), delayed
      speech(6/12), excessive sweating(7/12), optic atrophy(1/12), epilepsy(1/12),
      palmoplantar hyperkeratosis(5/12), multiple dental caries(9/12), atrophy of the
      thenar/hypothenar muscles(4/12) and short stature(4/12) were detected.
    explanation: Documents sudomotor autonomic dysfunction in 7 of 12 patients.
- category: Neurological
  name: Cerebellar ataxia
  description: >-
    Late-onset, progressive cerebellar ataxia as part of the central-nervous-system
    involvement seen in triple A syndrome.
  phenotype_term:
    preferred_term: Progressive cerebellar ataxia
    term:
      id: HP:0002073
      label: Progressive cerebellar ataxia
  evidence:
  - reference: PMID:11062474
    reference_title: "Mutant WD-repeat protein in triple-A syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "late-onset progressive neurological symptoms (including cerebellar ataxia, peripheral neuropathy and mild dementia) suggest that the central nervous system may be involved in the disease as well"
    explanation: Cerebellar ataxia is part of the late-onset progressive CNS phenotype.
- category: Neurological
  name: Dementia
  description: >-
    Mild dementia as a component of the late-onset central-nervous-system
    neurodegeneration.
  phenotype_term:
    preferred_term: Mild dementia
    term:
      id: HP:0000726
      label: Dementia
  evidence:
  - reference: PMID:11062474
    reference_title: "Mutant WD-repeat protein in triple-A syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "late-onset progressive neurological symptoms (including cerebellar ataxia, peripheral neuropathy and mild dementia) suggest that the central nervous system may be involved in the disease as well"
    explanation: Mild dementia is part of the late-onset progressive CNS phenotype.
- category: Neurological
  name: Optic atrophy
  description: Optic atrophy is a recognized later neurological manifestation.
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:20687490
    reference_title: Triple-A syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Polyneuropathy, amyotrophy, optic atrophy are the other common neurological problems."
    explanation: Lists optic atrophy among the neurological manifestations.
- category: Neurological
  name: Skeletal muscle atrophy
  description: Amyotrophy can accompany progressive neurological involvement.
  phenotype_term:
    preferred_term: Skeletal muscle atrophy
    term:
      id: HP:0003202
      label: Skeletal muscle atrophy
  evidence:
  - reference: PMID:20687490
    reference_title: Triple-A syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Polyneuropathy, amyotrophy, optic atrophy are the other common neurological problems."
    explanation: Lists amyotrophy among the neurological manifestations.
- category: Dermatologic
  name: Hyperpigmentation of the skin
  description: >-
    Cutaneous and oral hyperpigmentation can accompany ACTH-resistant primary
    adrenal insufficiency.
  phenotype_term:
    preferred_term: Hyperpigmentation of the skin
    term:
      id: HP:0000953
      label: Hyperpigmentation of the skin
  evidence:
  - reference: PMID:25554662
    reference_title: '[Allgrove syndrome].'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "presented oral hyperpigmentation and diffused acquired melanoderma"
    explanation: Documents oral and diffuse cutaneous hyperpigmentation.
- category: Dermatologic
  name: Palmoplantar hyperkeratosis
  frequency: FREQUENT
  description: Palmoplantar keratoderma is a recognized dermatologic manifestation.
  phenotype_term:
    preferred_term: Palmoplantar keratoderma
    term:
      id: HP:0000982
      label: Palmoplantar keratoderma
  evidence:
  - reference: PMID:36194344
    reference_title: "The clinical and laboratory features of patients with triple A syndrome: a single-center experience in Turkey."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, hyperreflexia(6/12), learning disability(5/12), hypernasal
      speech(5/12), muscle weakness(8/12), delayed walking(7/12), delayed
      speech(6/12), excessive sweating(7/12), optic atrophy(1/12), epilepsy(1/12),
      palmoplantar hyperkeratosis(5/12), multiple dental caries(9/12), atrophy of the
      thenar/hypothenar muscles(4/12) and short stature(4/12) were detected.
    explanation: >-
      Documents palmoplantar hyperkeratosis in 5 of 12 patients, supporting the
      FREQUENT band (30-79%).
pathophysiology:
- name: ALADIN loss and nuclear pore complex mislocalization
  description: >-
    ALADIN is a WD-repeat nucleoporin that normally localizes to the nuclear
    pore complex (NPC), the sole gateway for nucleocytoplasmic transport.
    Disease-associated missense, nonsense, and frameshift AAAS mutations fail
    to target ALADIN to the NPC, leaving it mislocalized in the cytoplasm.
    Nuclear envelopes and NPCs are structurally normal, so disease arises from
    a defect in NPC function rather than structure.
  genes:
  - preferred_term: AAAS
    term:
      id: hgnc:13666
      label: AAAS
  biological_processes:
  - preferred_term: nucleocytoplasmic transport
    term:
      id: GO:0006913
      label: nucleocytoplasmic transport
  cellular_components:
  - preferred_term: nuclear pore
    term:
      id: GO:0005643
      label: nuclear pore
  evidence:
  - reference: PMID:12730363
    reference_title: "The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We showed previously that ALADIN localizes to nuclear pore complexes (NPCs), large multiprotein assemblies that are the sole sites of nucleocytoplasmic transport."
    explanation: Establishes ALADIN as a nuclear pore complex protein central to nucleocytoplasmic transport.
  - reference: PMID:12730363
    reference_title: "The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "A variety of disease-associated missense, nonsense, and frameshift mutations failed to localize to NPCs and were found predominantly in the cytoplasm."
    explanation: Shows disease mutations mislocalize ALADIN away from the NPC into the cytoplasm.
  downstream:
  - target: Selective failure of nuclear protein import
    description: NPC mistargeting of ALADIN disrupts NPC function and selective nuclear import.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:12730363
      reference_title: "The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "these findings indicate that defects in NPC function, rather than structure, give rise to triple A syndrome"
      explanation: Links ALADIN mislocalization to a functional NPC defect that drives disease.
- name: Selective failure of nuclear protein import
  description: >-
    Mistargeted ALADIN selectively impairs the karyopherin (importin)
    alpha/beta-mediated import pathway, decreasing nuclear accumulation of
    specific cargoes including the DNA single-strand-break repair protein
    aprataxin (APTX) and DNA ligase I, while sparing other import pathways.
  biological_processes:
  - preferred_term: protein import into nucleus
    term:
      id: GO:0006606
      label: protein import into nucleus
  cellular_components:
  - preferred_term: nuclear pore
    term:
      id: GO:0005643
      label: nuclear pore
  evidence:
  - reference: PMID:16467144
    reference_title: "ALADINI482S causes selective failure of nuclear protein import and hypersensitivity to oxidative stress in triple A syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ALADIN(I482S) affected a karyopherin-alpha/beta-mediated import pathway and decreased nuclear accumulations of aprataxin (APTX), a repair protein for DNA single-strand breaks (SSBs), and of DNA ligase I in I482Sf."
    explanation: Demonstrates selective impairment of nuclear import of DNA-repair proteins by mutant ALADIN.
  downstream:
  - target: Impaired DNA repair and oxidative stress hypersensitivity
    description: Reduced nuclear import of aprataxin and DNA ligase I compromises repair of DNA single-strand breaks.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16467144
      reference_title: "ALADINI482S causes selective failure of nuclear protein import and hypersensitivity to oxidative stress in triple A syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "indicating that ALADIN(I482S) selectively impaired transport of discrete import complexes through NPC"
      explanation: Selective import failure of repair factors links directly to a downstream DNA-repair deficit.
- name: Impaired DNA repair and oxidative stress hypersensitivity
  description: >-
    Deficient nuclear delivery of DNA single-strand-break repair machinery
    renders triple A syndrome cells hypersensitive to oxidative stress: on
    glutathione depletion, patient fibroblasts accumulate DNA single-strand
    breaks that they can no longer sufficiently repair. This nuclear oxidative
    vulnerability is proposed as a primary driver of the tissue-specific
    degeneration.
  biological_processes:
  - preferred_term: single strand break repair
    term:
      id: GO:0000012
      label: single strand break repair
  - preferred_term: DNA repair
    term:
      id: GO:0006281
      label: DNA repair
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:16467144
    reference_title: "ALADINI482S causes selective failure of nuclear protein import and hypersensitivity to oxidative stress in triple A syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Cell survival assay showed hypersensitivity of I482Sf to l-buthionine-(S,R)-sulfoximine (BSO), a glutathione-depleting agent."
    explanation: Demonstrates hypersensitivity of patient cells to oxidative (glutathione-depleting) stress.
  - reference: PMID:16467144
    reference_title: "ALADINI482S causes selective failure of nuclear protein import and hypersensitivity to oxidative stress in triple A syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These observations implied that I482Sf are hypersensitive to BSO and no longer sufficiently repair SSBs."
    explanation: Links oxidative stress to an unrepaired DNA single-strand-break burden in patient cells.
  downstream:
  - target: Tissue-specific cellular degeneration
    description: Accumulated oxidative DNA damage in vulnerable cell types drives their degeneration.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:12730363
      reference_title: "The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "ALADIN plays a cell type-specific role in regulating nucleocytoplasmic transport"
      explanation: Supports a cell-type-specific transport role whose failure underlies selective tissue degeneration.
- name: Tissue-specific cellular degeneration
  description: >-
    The ALADIN nucleocytoplasmic-transport defect selectively affects tissues
    with high expression and dependence, producing adrenocortical failure,
    peripheral and central neurodegeneration, autonomic dysfunction, lacrimal
    gland hypofunction (alacrima), and oesophageal motor dysfunction
    (achalasia). ALADIN is expressed in neuroendocrine and cerebral structures,
    consistent with a role in normal development and maintenance of the
    peripheral and central nervous systems.
  cell_types:
  - preferred_term: cortical cell of adrenal gland
    term:
      id: CL:0002097
      label: cortical cell of adrenal gland
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: autonomic neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  locations:
  - preferred_term: adrenal gland
    term:
      id: UBERON:0002369
      label: adrenal gland
  - preferred_term: lacrimal gland
    term:
      id: UBERON:0001817
      label: lacrimal gland
  - preferred_term: esophagus
    term:
      id: UBERON:0001043
      label: esophagus
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  evidence:
  - reference: PMID:11062474
    reference_title: "Mutant WD-repeat protein in triple-A syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The expression of the gene in both neuroendocrine and cerebral structures points to a role in the normal development of the peripheral and central nervous systems."
    explanation: Supports tissue-specific (neuroendocrine and CNS) vulnerability driven by ALADIN expression pattern.
  downstream:
  - target: ACTH-resistant adrenal cortical failure
    description: Degeneration of adrenocortical cells produces ACTH-resistant glucocorticoid deficiency.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:11062474
      reference_title: "Mutant WD-repeat protein in triple-A syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "an autosomal recessive disorder characterized by adrenocorticotropin hormone (ACTH)-resistant adrenal insufficiency, achalasia of the oesophageal cardia and alacrima"
      explanation: Adrenocortical failure manifests as the ACTH-resistant adrenal insufficiency of the triad.
  - target: Achalasia
    description: Oesophageal tissue and autonomic dysfunction produce achalasia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:11062474
      reference_title: "Mutant WD-repeat protein in triple-A syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "an autosomal recessive disorder characterized by adrenocorticotropin hormone (ACTH)-resistant adrenal insufficiency, achalasia of the oesophageal cardia and alacrima"
      explanation: Identifies achalasia as a defining distal manifestation.
  - target: Dysphagia
    description: Achalasia caused by oesophageal dysfunction produces dysphagia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Achalasia
    evidence:
    - reference: PMID:42415167
      reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "recurring symptoms of dysphagia due to achalasia"
      explanation: Directly states that dysphagia is due to achalasia.
  - target: Alacrima
    description: Lacrimal gland and autonomic dysfunction produce alacrima.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:11062474
      reference_title: "Mutant WD-repeat protein in triple-A syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "an autosomal recessive disorder characterized by adrenocorticotropin hormone (ACTH)-resistant adrenal insufficiency, achalasia of the oesophageal cardia and alacrima"
      explanation: Identifies alacrima as a defining distal manifestation.
  - target: Peripheral neuropathy
    description: Peripheral neuronal degeneration produces peripheral neuropathy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:11062474
      reference_title: "Mutant WD-repeat protein in triple-A syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "late-onset progressive neurological symptoms (including cerebellar ataxia, peripheral neuropathy and mild dementia) suggest that the central nervous system may be involved in the disease as well"
      explanation: Supports peripheral neuropathy within the progressive neurological phenotype.
  - target: Autonomic dysfunction
    description: Degeneration and abnormal development of autonomic neurons produce dysautonomia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:11062474
      reference_title: "Mutant WD-repeat protein in triple-A syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "several lines of evidence indicate that triple-A syndrome results from the abnormal development of the autonomic nervous system"
      explanation: Supports autonomic nervous system dysfunction as a disease consequence.
  - target: Cerebellar ataxia
    description: Central neurodegeneration produces progressive cerebellar ataxia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:11062474
      reference_title: "Mutant WD-repeat protein in triple-A syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "late-onset progressive neurological symptoms (including cerebellar ataxia, peripheral neuropathy and mild dementia) suggest that the central nervous system may be involved in the disease as well"
      explanation: Supports cerebellar ataxia as part of central nervous system involvement.
  - target: Dementia
    description: Central neurodegeneration produces cognitive decline and dementia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:11062474
      reference_title: "Mutant WD-repeat protein in triple-A syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "late-onset progressive neurological symptoms (including cerebellar ataxia, peripheral neuropathy and mild dementia) suggest that the central nervous system may be involved in the disease as well"
      explanation: Supports mild dementia as part of central nervous system involvement.
  - target: Optic atrophy
    description: Progressive neurological degeneration can produce optic atrophy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20687490
      reference_title: Triple-A syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Polyneuropathy, amyotrophy, optic atrophy are the other common neurological problems."
      explanation: Places optic atrophy within the neurological disease spectrum.
  - target: Skeletal muscle atrophy
    description: Progressive neurological degeneration can produce amyotrophy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20687490
      reference_title: Triple-A syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Polyneuropathy, amyotrophy, optic atrophy are the other common neurological problems."
      explanation: Places amyotrophy within the neurological disease spectrum.
- name: ACTH-resistant adrenal cortical failure
  description: >-
    Selective loss of adrenocortical function produces isolated glucocorticoid
    deficiency that does not respond to ACTH, the endocrine hallmark of the
    syndrome and a potentially life-threatening feature if unrecognized.
  cell_types:
  - preferred_term: cortical cell of adrenal gland
    term:
      id: CL:0002097
      label: cortical cell of adrenal gland
  locations:
  - preferred_term: adrenal cortex
    term:
      id: UBERON:0001235
      label: adrenal cortex
  evidence:
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He was diagnosed with primary adrenal insufficiency in childhood and substituted with fludrocortisone and hydrocortisone."
    explanation: Documents primary adrenal insufficiency managed with corticosteroid replacement.
  downstream:
  - target: ACTH-resistant primary adrenal insufficiency
    description: Adrenal cortical failure directly manifests as primary adrenal insufficiency.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:11062474
      reference_title: "Mutant WD-repeat protein in triple-A syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "an autosomal recessive disorder characterized by adrenocorticotropin hormone (ACTH)-resistant adrenal insufficiency, achalasia of the oesophageal cardia and alacrima"
      explanation: Directly identifies ACTH-resistant adrenal insufficiency as a defining manifestation.
  - target: Hyperpigmentation of the skin
    description: Adrenal insufficiency with elevated ACTH can manifest as mucocutaneous hyperpigmentation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Elevated ACTH and melanocortin receptor stimulation
    evidence:
    - reference: PMID:25554662
      reference_title: '[Allgrove syndrome].'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        presented oral hyperpigmentation and diffused acquired melanoderma, as
        well as long-standing dry-eye syndrome. Laboratory tests confirmed low
        adrenal insufficiency.
      explanation: Co-documents hyperpigmentation and laboratory-confirmed adrenal insufficiency.
treatments:
- name: Glucocorticoid replacement (hydrocortisone)
  description: >-
    Lifelong glucocorticoid replacement with hydrocortisone corrects the
    ACTH-resistant glucocorticoid deficiency and prevents adrenal crisis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: hydrocortisone
      term:
        id: CHEBI:17650
        label: cortisol
  target_phenotypes:
  - preferred_term: ACTH-resistant primary adrenal insufficiency
    term:
      id: HP:0008207
      label: Primary adrenal insufficiency
  target_mechanisms:
  - target: ACTH-resistant adrenal cortical failure
    treatment_effect: BYPASSES
    description: Exogenous glucocorticoid bypasses failed endogenous cortisol production.
    evidence:
    - reference: PMID:42415167
      reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "He was diagnosed with primary adrenal insufficiency in childhood and substituted with fludrocortisone and hydrocortisone."
      explanation: Hydrocortisone replacement is used to manage the adrenal insufficiency of triple A syndrome.
- name: Mineralocorticoid replacement (fludrocortisone)
  description: >-
    Fludrocortisone provides mineralocorticoid replacement when the adrenal
    insufficiency includes a mineralocorticoid component.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: fludrocortisone
      term:
        id: CHEBI:50885
        label: fludrocortisone
  target_phenotypes:
  - preferred_term: ACTH-resistant primary adrenal insufficiency
    term:
      id: HP:0008207
      label: Primary adrenal insufficiency
  target_mechanisms:
  - target: ACTH-resistant adrenal cortical failure
    treatment_effect: BYPASSES
    description: Exogenous mineralocorticoid bypasses deficient endogenous adrenal output.
    evidence:
    - reference: PMID:42415167
      reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "He was diagnosed with primary adrenal insufficiency in childhood and substituted with fludrocortisone and hydrocortisone."
      explanation: Fludrocortisone replacement is part of the corticosteroid substitution used in triple A syndrome.
- name: Heller myotomy for achalasia
  description: >-
    Surgical Heller myotomy relieves the functional obstruction of oesophageal
    achalasia and its associated dysphagia.
  treatment_term:
    preferred_term: Heller Myotomy
    term:
      id: NCIT:C157873
      label: Heller Myotomy
  target_phenotypes:
  - preferred_term: Achalasia
    term:
      id: HP:0002571
      label: Achalasia
  - preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "recurring symptoms of dysphagia due to achalasia, who was previously treated by Heller myotomy and repeated endoscopic dilations"
    explanation: Documents Heller myotomy as management for achalasia.
- name: Endoscopic dilation for achalasia
  description: >-
    Repeated endoscopic dilation lowers functional oesophageal obstruction and
    relieves dysphagia.
  treatment_term:
    preferred_term: Esophageal Dilation
    term:
      id: NCIT:C70908
      label: Esophageal Dilation
  target_phenotypes:
  - preferred_term: Achalasia
    term:
      id: HP:0002571
      label: Achalasia
  - preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "recurring symptoms of dysphagia due to achalasia, who was previously treated by Heller myotomy and repeated endoscopic dilations"
    explanation: Documents repeated endoscopic dilation as management for achalasia.
- name: Ocular lubrication for alacrima
  description: >-
    Supportive ocular lubrication (artificial tears) protects the ocular
    surface from the keratopathy risk of deficient tear production.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Alacrima
    term:
      id: HP:0000522
      label: Alacrima
  evidence:
  - reference: PMID:20687490
    reference_title: Triple-A syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alacrimia is treated with artificial tears"
    explanation: Directly supports artificial tears for alacrima.
diagnosis:
- name: Schirmer tear-production test
  description: >-
    Schirmer testing objectively demonstrates deficient tear production and
    supports the alacrima component of the diagnostic triad.
  diagnosis_term:
    preferred_term: laboratory procedure
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  evidence:
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Schirmer test confirmed total alacrima"
    explanation: Documents objective confirmation of alacrima by Schirmer testing.
- name: AAAS molecular genetic testing
  description: >-
    Molecular analysis establishes biallelic pathogenic AAAS variants and can
    confirm Triple A syndrome when the clinical triad is incomplete.
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:42415167
    reference_title: "Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Long-read sequencing confirmed compound heterozygosity for two point mutations in the AAAS gene"
    explanation: Documents molecular confirmation of biallelic AAAS variants.
📚

References & Deep Research

Deep Research

1
Codex ▸
Triple A Syndrome — consolidated literature audit
gpt-5

Triple A Syndrome — consolidated literature audit

Scope and ontology anchor

Triple A syndrome (Allgrove syndrome) is anchored to MONDO:0009279 and to biallelic loss-of-function variation in AAAS (hgnc:13666), encoding the nuclear-pore protein ALADIN. The five duplicate PRs agreed on the disease identity, inheritance, defining clinical triad, and proximal molecular lesion. The final model treats it as a nucleoporin/neuroendocrine disorder rather than an inborn error of intermediary metabolism.

Verified source set

Reference Role in the final model
PMID:11062474 AAAS discovery, defining triad, autonomic and neurological spectrum
PMID:12730363 ALADIN nuclear-pore localization and mutant cytoplasmic mislocalization
PMID:16467144 Selective nuclear import failure, impaired repair, oxidative-stress sensitivity
PMID:20687490 Rarity, optic atrophy/amyotrophy, and organ-directed management
PMID:25554662 Clinical hyperpigmentation
PMID:36194344 Cohort evidence for dysautonomia and palmoplantar hyperkeratosis
PMID:42415167 Contemporary case, biallelic AAAS confirmation, Schirmer testing, replacement therapy, myotomy/dilation

The authoritative evidence inventory is the entry itself and its generated caches.

Reconciliation findings

Clinical completeness

The final phenotype set includes the classic triad of achalasia, alacrima, and ACTH-resistant primary adrenal insufficiency; dysphagia; central, peripheral, and autonomic neurological involvement; optic atrophy; amyotrophy; cutaneous hyperpigmentation; and palmoplantar keratoderma. Frequency is asserted only where a numeric cohort observation supports an ontology band.

Mechanism

The final pathograph preserves the best-supported causal sequence shared across the drafts: pathogenic AAAS variation and ALADIN mistargeting at the nuclear pore lead to selective nuclear-import failure, impaired delivery of DNA-repair factors, oxidative-stress hypersensitivity, tissue-selective degeneration, and adrenocortical failure. In-vitro molecular experiments remain tagged IN_VITRO; patient manifestations and treatment observations remain HUMAN_CLINICAL.

Diagnosis and management

The consolidated entry structures Schirmer testing and molecular confirmation instead of leaving diagnosis solely in prose. Management is separated into hydrocortisone and fludrocortisone replacement, Heller myotomy, endoscopic dilation, and artificial tears, with current NCIT procedure bindings and therapeutic agents where supported.

Prevalence discipline

The literature consistently calls the disorder rare but does not provide a robust denominator-based worldwide estimate in the fetched sources. The final entry therefore records a qualitative RARE class with measure_type: UNKNOWN; it does not convert case counts or founder observations into an unsupported numeric prevalence.

Excluded or deferred claims

  • Antioxidants and N-acetylcysteine remain mechanistic or in-vitro leads, not established clinical therapies.
  • No precise phenotype frequency is inferred from words such as “common.”
  • No numeric worldwide prevalence rate is fabricated.
  • Additional esophageal physiology tests may be curated when an exact, procedure-specific source is fetched.

Completeness conclusion

The five drafts were complementary: one had the strongest atomic mechanism, one the broadest phenotype coverage, and others supplied diagnosis, treatment, and review corrections. Their useful content is now represented once in the canonical YAML. Incremental histories, stale enum snapshots, and duplicate reference caches are not part of the consolidated change.